Hematopoietic Cell Transplantation in a Patient With X‐Linked Chronic Granulomatous Disease With McLeod Phenotype

Authors:

Abstract
Background: X‐linked chronic granulomatous disease (X‐CGD) may be associated with McLeod syndrome (MLS) as a contiguous gene deletion syndrome. MLS is characterized by the loss of XK protein along with Kx antigen on red blood cell (RBC) surfaces and late‐onset neurocognitive symptoms. RBCs in healthy donors express XK protein and related Kx antigen on the surface; therefore, transfusion from random donors to patients with MLS poses a risk of Kx sensitization, leading to severe hemolysis. As the radical treatment of X‐CGD is hematopoietic cell transplantation (HCT), treating patients with coexisting X‐CGD and MLS is extremely challenging.Method: A retrospective chart review was completed for a case of X‐CGD associated with MLS who underwent HCT.Result: A 7‐year‐old boy with X‐CGD and MLS underwent HCT from a matched unrelated donor (human leukocyte antigen, 7/8 matched). Rituximab was added to busulfan‐based reduced intensity conditioning to prevent Kx sensitization. Donor RBCs were depleted from the bone marrow before infusion to prevent Kx sensitization. Neutrophil engraftment was achieved on day +19 with full donor chimerism. No hemolytic events occurred, and he is living well 2 years after HCT.Conclusion: We were able to safely perform transplantation in a patient with X‐CGD and MLS by adding rituximab and depleting RBCs from the donor bone marrow. The long‐term impact of HCT on MLS is unclear. However, HCT may improve prognosis and quality of life by reducing recurrent infections caused by X‐CGD. Moreover, this HCT method is non‐invasive, relatively simple, and easily implementable.
Funding Information
  • National Center for Child Health and Development

This publication has 11 references indexed in Scilit: